In the earlier part of the pipeline, we’re taking some bigger risks and shooting for some big targets. And some of those will work and some of those won’t. We don’t know which ones or which yet, but we’re going to ride the winners, and the winners are going to be those ones that are highly differentiated. Dan, I want to give you a chance to weigh in here, too, if you’d like to add anything in particular about the translation of our commercial experience back to R&D choices.
Dan Swisher: Yes. Thanks, Bruce. So, I mean, one thing to take in mind is some of our pipeline is also evidence generation, new indications, new formulations of our existing brands, so we want to continue to unlock the full potential of those brands, including broadly Epidiolex and oxybate, and even on the oncology side. I mean, zani is a pipeline within a product, of course. And so, how we kind of think that through and where we can get the most differentiation and PTRS’, et cetera. So, it’s a great set of challenges that we’ve got with the pipeline and the commercial portfolio. And clearly remaining and enhancing our category leadership, and now epilepsy, sleep medicine, and increasingly, some of these areas in both solid and liquid tumors is also a incentive for the way we think about building out the pipeline.
And we have, under Rob’s leadership, really created much more internal capability all the way from filing our own INDs through development to also a corporate development muscle, which I’d say is second to none, where we can really look at external innovation. And folks are knocking on our door because of the success we’ve done in some of these partnerships, whether late-stage our early pipeline. So, it’s a good place to be, but we will move into some new areas, as Bruce referenced, where there’s significant unmet need and we think we can get to some smart go-no-go decision points.
Operator: Thank you. Our next question comes from Brandon Folkes with Cantor Fitzgerald. Your line is open.
Brandon Folkes: Hi, thanks for taking my question. Maybe just one on Zepzelca. Any updates on the enrollment and timeline expectations for LAGOON and IMforte? Any chance of getting the potential first-line move complete before or during 2025, just as you think about Vision 2025? Thank you.
Bruce Cozadd: Rob, do you want to talk about Zepzelca clinical trial expectations?
Rob Iannone: And I would maybe ask just for a reminder from our group in terms of what’s been communicated previously, but I would just say that, that trial is on track relative to expectations, and we really are quite excited about the potential that Zepzelca move up into the front-line where we’re pre-emptively treating patients before they progress, accessing more patients, treating patients for a longer duration of time. And — thank you. I am seeing now that we had said previously that we’re expecting a complete enrollment this year.
Bruce Cozadd: In the first-line trial.
Rob Iannone: Yes.
Operator: Thank you. Our next question comes from Ash Verma with UBS. Your line is open.
